Early-phase oncology trials carry substantial scientific and commercial risk in cancer drug development. Getting them right ...
Scientists at the Institute of Science Tokyo (Science Tokyo) have successfully realized the highly selective asymmetric 1,6 ...
Q4 2025 Earnings Call February 10, 2026 4:30 PM ESTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...
Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing ...
Evogene Ltd. , a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a ...
Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...
AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.
The key alterations sought are FGFR3 activating mutations or fusions/rearrangements (“susceptible” alterations), for potential use of the FGFR inhibitor erdafitinib (Balversa), and HER2 IHC expression ...
The Morgan Lewis cross-functional and cross-jurisdiction life sciences and healthcare teams were represented in San Francisco ...
Thank you, Jacquie, and good afternoon, everyone. Starting with our full year results, our HIV business grew 6% year over ...
If you've ever watched a glass blower at work, you've seen a material behaving in a very special way. As it cools, the viscosity of molten glass increases steadily but gradually, allowing it to be ...
Thank you, Francesca. As a result, we are raising guidance ranges and for our full year 2024 total revenues and adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results